Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition
International Journal of Molecular Sciences · 23.06.2026 · 27 (13) · 5664
DOI: 10.3390/ijms27135664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.06.2026. Verfasst von Juarez R Braga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Central Arkansas Veterans Health System, Little Rock, AR 72205, USA. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Mineralocorticoid Receptor Antagonists, Aldosterone, Cytochrome P-450 CYP11B2. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetic kidney disease (DKD) represents the single most common etiology of chronic kidney disease and end stage kidney disease globally, a burden that continues to expand in direct proportion to the worldwide growth of the diabetes epidemic. The pathogenesis of DKD is multifactorial, involving metabolic, hemodynamic, inflammatory, and fibrotic pathways. Among these, aldosterone has emerged as a key mediator of kidney injury, extending beyond its traditional role in sodium balance and blood pressure regulation. Through activation of both MR-dependent transcriptional processes and MR-independent signaling cascades, aldosterone drives a coordinated pattern of renal injury encompassing oxidative stress generation, endothelial dysfunction, podocyte damage, inflammatory cell recruitment, and progressive interstitial fibrosis. Current therapies targeting the renin–angiotensin–aldosterone system (RAAS), including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, have significantly improved outcomes in DKD. Despite these advances, a considerable degree of residual cardiovascular and renal risk persists, attributable in part to the incomplete attenuation of aldosterone activity and the well-characterized phenomenon of aldosterone escape under sustained RAAS blockade. Aldosterone synthase inhibitors (ASIs) represent a mechanistically distinct therapeutic approach that targets aldosterone overproduction at its enzymatic source, potentially addressing both MR-dependent and independent pathways. Early clinical trials evaluating the efficacy of ASIs have demonstrated promising effects on blood pressure and albuminuria. This review summarizes the role of aldosterone in DKD pathogenesis, evaluates current therapeutic approaches, and discusses emerging evidence supporting ASIs as a potential addition to the evolving treatment landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Central Arkansas Veterans Health System, Little Rock, AR 72205, USA.
- Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- FMC Global Medical Office, Medical Affairs, Fresenius Medical Care, Waltham, MA 02451, USA.
Zitieren
APA
Braga, J. R., Holthoff, J. H., Juncos, L. A., Thotakura, R., & Ayub, F. (2026). Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition. International Journal of Molecular Sciences, 27(13), 5664. https://doi.org/10.3390/ijms27135664
Vancouver
Braga JR, Holthoff JH, Juncos LA, Thotakura R, Ayub F. Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition. International Journal of Molecular Sciences. 2026;27(13):5664. doi:10.3390/ijms27135664
BibTeX
@article{Braga2026,
author = {Braga, Juarez R and Holthoff, Joseph H and Juncos, Luis A and Thotakura, Ramakrishna and Ayub, Fatima},
title = {Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5664},
doi = {10.3390/ijms27135664}
}
EUVIMED